Studies on the Persistence of Transgene Expression

Syahril Abdullah, Keble College, 2005.

Back   Download (4Mb)

Non-viral gene therapy is being considered as a potential treatment for chronic cystic fibrosis lung disease. In the murine airways, which have been used to model lung gene transfer, the resultant transgene expression is transient. One of the problems that hinders prolonged gene expression of pDNA gene transfer vectors in vivo is promoter attenuation. Pro-inflammatory cytokines, largely induced by the administration of the gene transfer vector, have been implicated in this phenomenon. This study investigated strategies designed to improve the persistence of transgene expression in the murine airways following delivery of cationic lipid GL67 complexed with pDNA. Three strategies were tested: (1) the incorporation of an insulator element to protect the promoter from attenuation, (2) the administration of an immunosuppressive drug to reduce pro-inflammatory cytokines, and (3) the modification of the pDNA construct itself. The addition of a putative insulator element, Ubiquitous Chromatin Opening Element (UCOE), 5' to a CMV promoter did not improve the duration of transgene expression. The administration of an immunosuppressive drug, dexamethasone, prior to pDNA delivery, only moderately reduced the pro-inflammatory cytokines with variable results on transgene activity. However, modification of the pDNA construct to fully deplete CpG sequences was shown to reduce the induction of pro-inflammatory cytokines and subsequently extend the duration of transgene expression up to 60 days post-administration although the precise mechanism is still questionable. These initial results have demonstrated that a potentially therapeutic level of transgene expression over an extended period may be achieved by the use of CpG-depleted plasmids in non-viral vectors.

Home
News
Introductory Videos
Medical Futures Innovation Award 2011
Twitter Feed
About Us
Contact Us
Careers
Resources
Lab Events
Environemental Policy
About this Site

Google Site Search

Site Feedback Form

All Site Images

 

UK CFGTC

How the Consortium works/FAQs

Consortium Website

Centre for Molecular Medicine, Edinburgh
The Roslin Institute
Dep of Gene Therapy, Imperial

Milestones

GL67A/pGM169

The Run-in Study

Single Dose Clinical Trial

Multi Dose Clinical Trial

 

Our Research

Non-viral Vector Development

Aerosol Mediated Gene Delivery

Viral Vector Development

Taqman Core Facility

Cystic Fibrosis

History of CF

Discovery of the CFTR Gene

CFTR Protein Structure

CFTR Function

CF Links

 

Gene Therapy

Introduction to Gene Therapy

Other CF Gene Therapy Groups

Why use Gene Therapy for CF

Target Cells for CF Gene Therapy

Barriers for CF Gene Therapy

Clinical Trials

Gene Therapy Successes

Gene Therapy Links

 

 

Publications

Papers in Journals

Conference Posters & Presentations

Book Chapters

D.Phil Theses

Lectures

 

Gene Therapy Seminars

Schedule

Directions & Venue